Company Description

OpGen, Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally.

The company’s products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits.

It provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services.

OpGen, Inc. was incorporated in 2001 and is headquartered in Rockville, Maryland.

OpGen, Inc.

Country	United States
IPO Date	May 5, 2015
Industry	Medical Devices
Sector	Healthcare
Employees	100
CEO	David Elliot Lazar

Contact Details

Address: 9717 Key West Avenue, Suite 100 Rockville, Maryland 20850 United States
Phone	301-869-9683
Website	opgen.com

Stock Details

Ticker Symbol	OPGN
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001293818
CUSIP Number	68373L307
ISIN Number	US68373L4068
Employer ID	06-1614015
SIC Code	8071

Key Executives

Name	Position
David Elliot Lazar	Chief Executive Officer and Chairman
Dr. Oliver Schacht Ph.D.	Executive Vice President of Corporate Development
Vadim Sapiro	Chief Information Officer

Latest SEC Filings

Date	Type	Title
Jul 8, 2024	10-Q	Quarterly Report
Jun 11, 2024	8-K	Current Report
Jun 3, 2024	10-K	Annual Report
Jun 3, 2024	8-K	Current Report
May 30, 2024	8-K/A	[Amend] Current report
May 24, 2024	8-K	Current Report
May 22, 2024	8-K	Current Report
May 17, 2024	NT 10-Q	Notification of inability to timely file Form 10-Q or 10-QSB
May 14, 2024	8-K	Current Report
Apr 29, 2024	8-K	Current Report

View All SEC Filings